

*October 8, 2015***Great Basin Scientific (Nasdaq/GBSN/Buy/\$0.08)**

Pulmatrix (Nasdaq/PULM/Buy/\$4.95)

Robert M. Wasserman

Director of Research

561-208-2905

rwasserman@dawsonjames.com

1) Great Basin Scientific (Nasdaq/GBSN/Buy/\$0.08) – Great Basin announced this morning that the Company has submitted its Shiga Toxin Direct Test to the US Food & Drug Administration (FDA) for 510(k) clearance. Upon clearance, this test would be the only stand-alone molecular test to detect Shiga toxin-producing *E. coli* (STEC) and the serotype O157 directly from a patient specimen. Conventional laboratory culture-based testing for STEC can be laborious and time-consuming, taking 48-96 hours to prepare and process the tests, while Great Basin's Shiga Toxin Direct Test offers true sample-to-result testing with less than three minutes of hands-on time, no specimen enrichment step, and presents much higher sensitivity than either non-molecular or antigen-based rapid tests. Once approved and commercially launched, labs will be able to run this panel on the same analyzer already used for Great Basin's two other commercial diagnostic assays, for *C. diff* and Group B *Strep*. This 510(k) marks the second such application recently made for the Company, following the late August 2015 submission for the Staph ID/R multiplex diagnostic assay. Both diagnostic tests currently awaiting 510(k) approving, Staph ID/R and now STEC, are expected to obtain clearance by the end of this year, allowing Great Basin to double its number of diagnostic assays available for use on its analyzer system from two to four at the start of 2016. We currently rate GBSN shares a Buy with a 12-18 month price target of \$10. **RMW**

2) Pulmatrix (Nasdaq/PULM/Buy/\$4.95) – Pulmatrix announced this morning that preclinical data has shown that its PUR1900 (iSPERSE-formulated itraconazole) was active and potent *in vitro* against *Aspergillus fumigatus*, a pathogen causing pulmonary infection in cystic fibrosis patients. The preclinical study also showed that PUR1900 achieved high lung concentrations and low systemic exposure in rats. The data will be presented today (10/8) at the 2015 North American Cystic Fibrosis Conference in Phoenix. In the study, researchers compared the pharmacokinetics and potency of itraconazole against two other antifungal compounds, amphotericin B and voriconazole. We currently rate PULM shares a Buy with a 12-18 month price target of \$15. **RMW**

Morning Notes provide current information we believe might be noteworthy to investors regarding the subject companies. Morning Notes are not intended to be complete research reports. More detailed information concerning the rated companies referenced in this Note, including the full reports, basis for price targets and other disclosures, may be found at:

http://dawsonjames.com/research_coverage.

Important Disclosures:

Dawson James Securities, Inc. (the "Firm") is a member of the Financial Industry Regulatory Authority ("FINRA") and the Securities Investor Protection Corporation ("SIPC").

The Firm does not make a market in the securities of the profiled company. The Firm has received investment banking compensation from the company (s) profiled in this report (PULM and GBSN) and may seek compensation for investment banking services in the future from the profiled company (s). The Firm has not received other compensation from the profiled company(s) in the last 12 months.

Neither the research analyst(s) whose name appears on this report nor any member of his (their) household is an officer, director or advisory board member of these companies. The Firm and/or its directors and employees may own securities of the company(s) in this report and may increase or decrease holdings in the future. As of September 30, 2015, the Firm as a whole did not beneficially own 1% or more of any class of common equity securities of the subject company (s) of this report (PULM and GBSN). The Firm, its officers, directors, analysts or employees may effect transactions in and have long or short positions in the securities (or options or warrants related to those securities) of the companies subject to this report. The Firm may effect transactions as principal or agent in those securities.

Analysts receive no direct compensation in connection with the Firm's investment banking business. All Firm employees, including the analyst(s) responsible for preparing this report, may be eligible to receive non-product or service specific monetary bonus compensation that is based upon various factors, including total revenues of the Firm and its affiliates as well as a portion of the proceeds from a broad pool of investment vehicles consisting of components of the compensation generated by investment banking activities, including but not limited to shares of stock and/or warrants, which may or may not include the securities referenced in this report.

Although the statements in this report have been obtained from and are based upon recognized statistical services, issuer reports or communications, or other sources that the Firm believes to be reliable, we cannot guarantee their accuracy. All opinions and estimates included in this report constitute the analyst's judgment as of the date of this report and are subject to change without notice.

The securities of the company discussed in this report may be unsuitable for investors depending on their specific investment objectives and financial position. This report is offered for informational purposes only, and does not constitute an offer or solicitation to buy or sell any securities discussed herein in any jurisdiction where such would be prohibited. Additional information is available upon request.

Ratings Definitions:

- 1) **Buy:** the analyst believes the price of the stock will appreciate and produce a total return Of at least 20% over the next 12-18 months;
- 2) **Neutral:** the analyst believes the price of the stock is fairly valued for the next 12-18 Months;
- 3) **Sell:** the analyst believes the price of the stock will decline by at least 20% over the next 12-18 months and should be sold.

The following chart reflects the range of current research report ratings for all companies followed by the analysts of the Firm. The chart also reflects the research report ratings relating to those companies for which the Firm has performed investment banking services.

Ratings Distribution	Company Coverage		Investment Banking	
	# of Companies	% of Total	# of Companies	% of Totals
Market Outperform (Buy)	18	75%	12	67%
Market Perform (Neutral)	6	25%	4	67%
Market Underperform (Sell)	0	0%	0	0%
Total	24	100%	16	67%

Analyst Certification:

The analyst(s) whose name appears on this research report certifies that 1) all of the views expressed in this report accurately reflect his (their) personal views about any and all of the subject securities or issuers discussed; and 2) no part of the research analyst's compensation was, is, or will be directly or indirectly related to the specific recommendations or views expressed by the research analyst in this research report; and 3) all Dawson James employees, including the analyst(s) responsible for preparing this research report, may be eligible to receive non-product or service specific monetary bonus compensation that is based upon various factors, including total revenues of Dawson James and its affiliates as well as a portion of the proceeds from a broad pool of investment vehicles consisting of components of the compensation generated by investment banking activities, including but not limited to shares of stock and/or warrants, which may or may not include the securities referenced in this report.